Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial

Journal of NeuroVirology

Volumn 24, Issue 1, 2018, Pages 16-27

  Sacktor, Ned ^a,b   Skolasky, Richard L ^a   Moxley, Richard ^a   Wang, Sheng ^a   Mielke, Michelle M ^c   Munro, Cynthia ^a   Steiner, Joseph ^d   Nath, Avindra ^d   Haughey, Norman ^a   McArthur, Justin ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cognitive impairment; Fluconazole; HIV; Paroxetine

Indexed keywords

BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CERAMIDE DERIVATIVE; FLUCONAZOLE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE ANTIGEN; NEOPTERIN; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN HEAVY CHAIN; NEUROFILAMENT PROTEIN LIGHT CHAIN; PAROXETINE; PLACEBO; PROTEIN CARBONYL; PROTEIN DERIVATIVE; SOLUBLE CD14 ANTIGEN; SOLUBLE CD163 ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; NEUROPROTECTIVE AGENT;

ACTIVITY OF DAILY LIVING ASSESSMENT; ADULT; ARTICLE; CALIFORNIA COMPUTERIZED ASSESSMENT PACKAGE SEQUENTIAL REACTION TIME TEST; CELL STRESS; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL OUTCOME; COGNITION; COGNITION ASSESSMENT; COGNITIVE FUNCTION TEST; COMBINATION DRUG THERAPY; COMPUTERIZED ASSESSMENT OF MILD COGNITIVE IMPAIRMENT TEST; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; EVIDENCE BASED PRACTICE; FACTORIAL DESIGN; FAS VERBAL FLUENCY TEST; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GLOBAL DEFICIT SCALE; GROOVED PEGBOARD TEST; HEADACHE; HIV ASSOCIATED DEMENTIA; HOPKINS VERBAL LEARNING TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFLAMMATION; INSOMNIA; INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LETTER NUMBER SEQUENCING TEST; MALE; MODIFIED MEDICATION MANAGEMENT TEST; MONOTHERAPY; MOTOR DYSFUNCTION ASSESSMENT; NAUSEA; NERVOUS SYSTEM INJURY; NEUROPSYCHOLOGICAL TEST; NPZ8 SCORE; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA; PRELIMINARY DATA; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RANDOMIZED CONTROLLED TRIAL; REY OSTERRIETH COMPLEX FIGURE TEST; SEXUAL DYSFUNCTION; STROOP TEST; SYMBOL DIGIT MODALITIES TEST; TIMED GAIT TEST; TRAIL MAKING TEST; TREATMENT RESPONSE; UNPLEASANT DREAM; VIRUS LOAD; XEROSTOMIA; DRUG ADMINISTRATION; DRUG REPOSITIONING; FACTOR ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PATHOGENICITY; PATHOPHYSIOLOGY; PATIENT SAFETY; PSYCHOLOGY; TREATMENT OUTCOME; VIROLOGY;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG REPOSITIONING; FACTOR ANALYSIS, STATISTICAL; FEMALE; FLUCONAZOLE; HIV-1; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PAROXETINE; PATIENT SAFETY; TREATMENT OUTCOME;

EID: 85031931879     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-017-0587-z     Document Type: Article

References (37)

1. Borkowski J, Benton A, Spreen O (1967) Word fluency and brain damage. Neuropsychologia 5:135–140
2. Brandt J (1991) The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol 5:125–142
3. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26:307–319
4. Choi J, Hahn S, Rhie D, Yoon S, Jo Y, Kim M (1999) Mechanism of fluoxetine block of cloned voltage-activated potassium channel Kv1.3. J Pharmacol Exp Ther 291:1–6
5. Choi B, Choi J, Ahn H, Kim MJ, Rhie D, Yoon S, Min D, Jo Y, Kim MS, Hahn S (2003) Fluoxetine blocks cloned neuronal A-type K+ channels Kv1.4. Neuroreport 14:2451–2455
6. Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM (2002) A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 59:1568–1573
7. Comalli PE Jr, Wapner S, Werner H (1962) Interference effects of Stroop color-word test in childhood, adulthood, and aging. J Genet Psychol 100:47–53
8. Epstein LG, Gendelman HE (1993) Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol 33:429–436
9. Galgani S, Balestra P, Narciso P, Tozzi V, Sette P, Pau F, Visco G (1997) Nimodipine plus zidovudine versus zidovudine alone in the treatment of HIV-1-associated cognitive deficits. AIDS (London, England) 11:1520–1521
10. Gandhi NS, Skolasky RL, Peters KB, Moxley RTT, Creighton J, Roosa HV, Selnes OA, McArthur J, Sacktor N (2011) A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. J Neurovirol 17:159–165
11. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, Turchan J, Nath A, Mattson MP (2004) Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55:257–267
12. Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts WL, Stover ES (1998) Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 55:41–51
13. Klove H (1963) Clinical neuropsychology. Med Clin N Am 47:1647–1658
14. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M (2007) Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69:1404–1410
15. McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67:699–714
16. Meulendyke KA, Queen SE, Engle EL, Shirk EN, Liu J, Steiner JP, Nath A, Tarwater PM, Graham DR, Mankowski JL, Zink MC (2014) Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. J Neurovirol 20:591–602
17. Miller EN (1990) California Computerized Assessment Package, (CALCAP). CALCAP, Los Angeles
18. Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, Yiannoutsos C, Zaborski L, Lipton SA (1998) A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 51:221–228
19. Osterrieth PA (1944) Le test de copie d’une figure complexe: contribution a l’etude de la perception et de la memoire. Arch Psychol 30:206–356
20. Perchenet L, Hilfiger L, Mizrahi J, Clement-Chomienne O (2001) Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5. J Pharmacol Exp Ther 298:1108–1119
21. Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401
22. Reitan R (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8:271–276
23. Reitan R (1979) Manual for administration of neuropsychological test batteries for adults and children. In: Laboratory N (ed) Neuropsychology laboratory. Neuropsychology Laboratory, Tucson
24. Rosenthal LS, Skolasky RL, Moxley RT, Roosa HV, Selnes OA, Eschman A, McArthur JC, Sacktor N (2013) A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder. J Neurovirol 19:432–441
25. Sacktor NC (1997) The Dana Consortium on the therapy for HIV Dementia and related cognitive disorders. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. Neurology 49:142–146
26. Sacktor N (1998) The Dana Consortium on the therapy for HIV Dementia and related cognitive disorders: a randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in HIV-associated cognitive impairment. Neurology 50:645–651
27. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K (2000) Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 54:233–235
28. Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, Paul R, Robertson K, Jarocki B, Scarsi K, Coombs RW, Zink MC, Nath A, Smith E, Ellis RJ, Singer E, Weihe J, McCarthy S, Hosey L, Clifford DB (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77:1135–1142
29. Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-associated neurocognitive disorder-pathogenesis and prospects for treatment. Nat Rev Neurol 12:309
30. Schifitto G, Sacktor N, Marder K, McDermott M, McArthur J, Kieburtz K, Small S, Epstein LG (1999) Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology 53:391–396
31. Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA (2007a) Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (London, England) 21:1877–1886
32. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, Hung VL, Miller EN, Smith E, Ellis RJ, Valcour V, Singer E, Marra CM, Kolson D, Weihe J, Remmel R, Katzenstein D, Clifford DB (2007b) A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 69:1314–1321
33. Schifitto G, Yiannoutsos CT, Ernst T, Navia BA, Nath A, Sacktor N, Anderson C, Marra CM, Clifford DB (2009) Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 73:1975–1981
34. Smith A (1968) The symbol digit modalities test: a neuropsychologic test of learning and other cerebral disorders. Special Child Publications, Seattle, Washington
35. Steiner JP, Bachani M, Wolfson-Stofko B, Lee MH, Wang T, Li G, Li W, Strayer D, Haughey NJ, Nath A (2015) Interaction of paroxetine with mitochondrial proteins mediates neuroprotection. Neurotherapeutics 12:200–216
36. Uthman OA, Abdulmalik JO (2008) Adjunctive therapies for AIDS dementia complex. The Cochrane database of systematic reviews, Cd006496
37. Yeung SY, Millar JA, Mathie A (1999) Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine. Br J Pharmacol 128:1609–1615